Across the four most common types of cancer, our results are outstanding. In recent tests, SpotitEarly’s non-invasive, scalable and cost-effective screening solution delivered exceptional accuracy, detecting cancer with 93.9% sensitivity and 94.3% specificity.

At the heart of our solution is LUCID, an advanced Bio-AI hybrid platform that fuses the extraordinary scent-detection abilities of trained dogs with cutting-edge AI precision. From easy, pain-free breath sample collection to real-time data analysis, SpotitEarly delivers highly accurate, actionable screening results that set new quality standards in healthcare.